We conclude that FRα is a favorable tumor-specific target, but EC17 lacks the full set of requirements for fluorescence-guided surgery in FRα-positive ovarian and breast cancer, especially because of autofluorescence and insufficient penetration depth. The gene discussed is FOLR1; the disease is neoplasm.